<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="498">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522960</url>
  </required_header>
  <id_info>
    <org_study_id>UZB-NEU-002</org_study_id>
    <nct_id>NCT04522960</nct_id>
  </id_info>
  <brief_title>Melatonin in Alzheimer's Disease: Effect on Disease Progression and Epileptiform Activity.</brief_title>
  <acronym>MADE</acronym>
  <official_title>Melatonin in Alzheimer's Disease: Effect on Disease Progression and Epileptiform Activity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term, prospective, observational study to investigate and compare the levels&#xD;
      and rhythm of melatonin in patients with AD dementia, mild cognitive impairment due to AD and&#xD;
      healthy volunteers. The investigators would like to validate the use of salivary and urine&#xD;
      melatonin measurements as an alternative for blood/CSF melatonin. Furthermore, the&#xD;
      investigators would like to assess the effects of melatonin levels on cognition by&#xD;
      correlating the levels and changes on cognitive tasks over a two year time frame. The&#xD;
      investigators will also investigate whether these effects could be due to its anticonvulsive&#xD;
      properties.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melatonin production gets disrupted in AD, as shown in post-mortem pineal glands and CSF of&#xD;
      AD patients. CSF melatonin levels are known to significantly drop in patients with&#xD;
      Alzheimer's dementia. It is known that CSF melatonin levels are much higher than blood&#xD;
      melatonin levels, due to melatonin secretion from the pineal recess directly into the third&#xD;
      ventricle. It has never been investigated whether blood melatonin accurately correlates with&#xD;
      CSF melatonin in AD, nor whether saliva or urine melatonin levels accurately reflect&#xD;
      blood/CSF melatonin in the AD continuum. The investigators want to validate the use of blood,&#xD;
      saliva and urine melatonin levels as alternative for CSF melatonin in the AD continuum to&#xD;
      pave the way for further use of less invasive collection techniques (blood, saliva, urine&#xD;
      instead of CSF) and to possibly study circadian rhythm in a less disrupting, in home&#xD;
      environment (saliva, urine).&#xD;
&#xD;
      Furhtermore, melatonin exerts several potential anti-AD properties, including&#xD;
      anti-inflammatory, anti-oxidant, tilting APP processing towards the non-amyloidogenic&#xD;
      pathway, exerting positive effects on sleep and so on. In vivo studies furthermore point to&#xD;
      anticonvulsive and antiepileptic effects of melatonin in a whole range of rodent models. Some&#xD;
      evidence exists for a role of melatonin in prevention of epileptic seizures in humans.&#xD;
&#xD;
      The investigators want to investigate influence of melatonin on changes in cognition in a&#xD;
      longitudinal way, and investigate influence on (sub)clinical epileptiform activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CSF and blood melatonin levels in patients with AD dementia, MCI due to AD and healthy volunteers</measure>
    <time_frame>24 hours</time_frame>
    <description>Comparison of CSF and blood melatonin levels between patients with MCI and dementia due to AD and healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood, saliva and urine melatonin correlations</measure>
    <time_frame>24 hours</time_frame>
    <description>Correlation between blood melatonin and urinary and salivary melatonin in the AD continuum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Melatonin influence on cognition</measure>
    <time_frame>2 years</time_frame>
    <description>Correlations between melatonin levels and cognitive performance over a 2 year time frame. This will be assessed by use of neuropsychological testing including MMSE, MoCA, RBANS, VAT, ...</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Melatonin influence on epileptiform activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Correlations between melatonin levels and (subclinical) epileptiform activity. Over a time frame of 8 weeks patients will undergo neuropsychological testing (with MMSE, MoCA, RBANS, VAT...), LTM-EEG monitoring (during 24 hours), MEG + hdEEG.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Patients with dementia or mild cognitive impairment due to AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dementia or MCI due to AD according to NIA-AA research criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Age-and-gender matched healthy controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MEG+hdEEG+MRI</intervention_name>
    <description>We will perform several tests:&#xD;
Neuropsychological testing to evaluate evolution of cognition during our study.&#xD;
Lumbar puncture, blood sampling, saliva and urine collection to assess melatonin levels at several timepoints within these biological fluids.&#xD;
MEG+hdEEG and MRI (to project MEG information) ; LTM-EEG to detect epileptiform activity in patients and healthy controls</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with dementia or mild cognitive impairment due to AD</arm_group_label>
    <other_name>Lumbar puncture</other_name>
    <other_name>Long-term EEG monitoring</other_name>
    <other_name>Blood sampling</other_name>
    <other_name>Saliva collection</other_name>
    <other_name>Urine collection</other_name>
    <other_name>Neuropsychological examination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Dementia due to AD, according to National Institute on Aging-Alzheimer's Association&#xD;
             (NIA-AA) criteria&#xD;
&#xD;
          2. MCI due to AD, according to NIA-AA criteria&#xD;
&#xD;
          3. Healthy controls: Age- and gender matched healthy controls&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients (AD dementia, MCI)&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Expected death due to illness within 2 years&#xD;
&#xD;
          -  Pacemaker or other ferrromagnetic material that is not MRI compatible&#xD;
&#xD;
          -  Other neurodegenerative or cerebrovascular disease&#xD;
&#xD;
          -  Pattern compatible with NPH (clinically, imaging)&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Multiple sclerosis or other demyelinating disease&#xD;
&#xD;
          -  Depression, psychosis or other mental disease&#xD;
&#xD;
          -  Use of anti-epileptic drugs&#xD;
&#xD;
          -  Alcohol or substance abuse&#xD;
&#xD;
          -  Korsakoff syndrome&#xD;
&#xD;
          -  Symptomatic liver disease&#xD;
&#xD;
          -  Uncontrolled thyroid disorders&#xD;
&#xD;
          -  Untreated HIV or syphilis&#xD;
&#xD;
          -  Clinically significant vitamin B12 deficiency&#xD;
&#xD;
          -  Severe systemic medical illness (eg end-stage cardiac disease, …)&#xD;
&#xD;
          -  Use of melatonin, agomelatine, or other sleep medications&#xD;
&#xD;
          -  Night worker&#xD;
&#xD;
          -  REM sleep behavior disorder, OSAS&#xD;
&#xD;
        Healthy controls&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Pacemaker or other ferromagnetic material that is not MRI compatible&#xD;
&#xD;
          -  Mild cognitive impairment or dementia of any cause&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Multiple sclerosis or other demyelinating disease&#xD;
&#xD;
          -  Depression, psychosis or other mental disease&#xD;
&#xD;
          -  Use of anti-epileptic drugs&#xD;
&#xD;
          -  Alcohol or substance abuse&#xD;
&#xD;
          -  Symptomatic liver disease&#xD;
&#xD;
          -  Uncontrolled thyroid disorders&#xD;
&#xD;
          -  Untreated HIV or syphilis&#xD;
&#xD;
          -  Clinically significant vitamin B12 deficiency&#xD;
&#xD;
          -  Severe systemic medical illness (eg end-stage cardiac disease, …)&#xD;
&#xD;
          -  Use of melatonin, agomelatine, or other sleep medications&#xD;
&#xD;
          -  Night worker&#xD;
&#xD;
          -  REM sleep behavior disorder, OSAS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sebastiaan Engelborghs, MD, PHD</last_name>
    <phone>02 477 64 10</phone>
    <email>sebastiaan.engelborghs@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amber Nous, MD</last_name>
    <phone>0479477937</phone>
    <email>amber.nous@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <state>Jette</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Nous, MD</last_name>
      <phone>+322 474 94 38</phone>
      <email>amber.nous@uzbrussel.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>May 17, 2022</last_update_submitted>
  <last_update_submitted_qc>May 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

